CB1 and CB2 Agonists Changed Estradiol in Opposite Directions in a Mouse Pain Model
Different cannabinoid receptor agonists did not produce one uniform hormone response in a mouse neuropathy experiment. The reported estradiol findings differed between CB1-selective and CB2-selective treatment, alongside sex-dependent differences in tolerance.
The experiment used chemotherapy-related neuropathy
Investigators studied male and female mice in a cisplatin-induced peripheral-neuropathy model. They compared selective CB1 agonism, selective CB2 agonism and a mixed agonist. These experimental compounds were not simply different retail cannabis strains.
Both pain-related and biological outcomes were recorded
The abstract reports faster development of tolerance to CB1-mediated antiallodynia in females than males, while the CB2-selective effect did not show tolerance development under the tested conditions. Female plasma estradiol decreased with selective CB1 agonism and increased with selective CB2 agonism.
Association is not an isolated causal pathway
Observing hormone changes alongside different tolerance patterns does not by itself establish that the hormone change caused the behavioral difference. The study also reported compound- and tissue-dependent changes in inflammatory and endocannabinoid-related gene expression.
Plasma estradiol is a hormone measurement, not a THC concentration or impairment marker. Mouse withdrawal from a mechanical stimulus is also different from a patient's report of pain relief. These distinctions prevent an attractive but unsupported shortcut from receptor selectivity to a human treatment recommendation. The findings motivate further work on sex, hormones and cannabinoid signaling without establishing that either receptor strategy is clinically superior.
Related: interpreting cannabis tolerance claims.
Research cited
Barnes RC; Blanton H; Dancel CL; Castro-Piedras I; Rorabaugh BR; Morgan DJ; Guindon J. Chronic Administration of Cannabinoid Agonists ACEA, AM1241, and CP55,940 Induce Sex-Specific Differences in Tolerance and Sex Hormone Changes in a Chemotherapy-Induced Peripheral Neuropathy. The Journal of pharmacology and experimental therapeutics (2024). doi:10.1124/jpet.124.002165. Findings discussed from the study abstract.
